Oxford, UK – 15 May 2023: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces the launch of its 4th generation lentiviral vector delivery system, TetraVectaTM. This state-of-the-art technology developed at Oxford Biomedica elevates the quality, potency and packaging capacity of… Read More
London, UK – 5 May 2023: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica”, “the Company” or “the Group”), a quality and innovation-led viral vector CDMO, gives notice that the Notice of Annual General Meeting (“AGM”) together with a copy of the … Read More
London, UK – 28 April 2023: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica”, “the Company” or “the Group”), a quality and innovation-led viral vector CDMO, gives notice that the 2022 Annual report and accounts is now available on the “Investors” section of the Group’s… Read More
Oxford, UK – 26th April 2023: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces the appointment of Ms Leone Patterson as an Independent Non-Executive Director. Ms Patterson shall join the Board on 1st May 2023. Ms Patterson has more than… Read More
Enhancing our position as a global quality and innovation-led viral vector CDMO Oxford, UK – 25 April 2023: Oxford Biomedica plc (“Oxford Biomedica” or “the Company”) (LSE: Oxford Biomedica), a quality and innovation-led viral vector CDMO, announces its preliminary results for the year ended 31 December 2022. Dr. Frank Mathias, Oxford… Read More
Oxford, UK – 13 March 2023: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, notes the statement by the US Treasury, Federal Reserve, and FDIC on 12 March 2023 announcing measures to protect all depositors of Silicon Valley Bank (“SVB”) in the… Read More
Dr Mathias brings a wealth of experience in innovation, contract development and manufacturing to Oxford Biomedica Stuart Henderson to take on newly created position of Vice Chair and Dame Kay Davies to become Senior Independent Director Oxford, UK – 20 February 2023: Oxford, UK – Oxford Biomedica (LSE:Oxford Biomedica), a leading… Read More
Oxford, UK – 27 January 2023: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces a change to the Group’s Board of Directors. Dr. Siyamak (“Sam”) Rasty has informed the Board that he will not be standing for re-election at the… Read More
Oxford, UK – 21 December 2022: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that Stuart Paynter, Chief Financial Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, 11 January 2023 at … Read More
Agreements signed with three new partners, bringing the total number of new AAV customers in 2022 to four, ahead of original target Oxford, UK – 14 December 2022: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that its subsidiary Oxford… Read More
Oxford, UK – 22 November 2022: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces the appointment of Dr Frank Mathias as Chief Executive Officer (CEO) and Board Director, effective March 2023. Dr Mathias brings world-class innovation and contract development and… Read More
Oxford, UK – 14 November 2022: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces exchange of contracts for the sale of its Windrush Court facility (the “Property”) to Kadans Science Partner (“Kadans”) for £60 million. Completion is due to… Read More